BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15704674)

  • 1. [Design, development and successful application of safe and effective HIV therapeutic and prophylactic vaccines].
    Abalaka JO
    Zhonghua Nan Ke Xue; 2005 Jan; 11(1):8-16. PubMed ID: 15704674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attempts to cure and prevent HIV/AIDS in central Nigeria between 1997 and 2002: opening a way to a vaccine-based solution to the problem?
    Abalaka JO
    Vaccine; 2004 Sep; 22(29-30):3819-28. PubMed ID: 15364427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic vaccination against HIV: current progress and future possibilities.
    Puls RL; Emery S
    Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why vaccines are not the answer - the failure of V520 and the importance of cell-mediated immunity in the fight against HIV.
    White A
    Med Hypotheses; 2008 Dec; 71(6):909-13. PubMed ID: 18768264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria.
    Egah DZ; Banwat EB; Audu ES; Iya D; Mandong BM; Anele AA; Gomwalk NE
    East Mediterr Health J; 2007; 13(4):961-6. PubMed ID: 17955779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi.
    Nyirenda M; Beadsworth MB; Stephany P; Hart CA; Hart IJ; Munthali C; Beeching NJ; Zijlstra EE
    J Infect; 2008 Jul; 57(1):72-7. PubMed ID: 18555534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV vaccines: brief review and discussion of future directions.
    Slobod KS; Bonsignori M; Brown SA; Zhan X; Stambas J; Hurwitz JL
    Expert Rev Vaccines; 2005 Jun; 4(3):305-13. PubMed ID: 16026246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.
    Leligdowicz A; Rowland-Jones S
    Expert Rev Vaccines; 2008 Apr; 7(3):319-31. PubMed ID: 18393602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination.
    Sun HY; Ko WC; Tsai JJ; Lee HC; Liu CE; Wong WW; Su SC; Ho MW; Cheng SH; Yang CH; Lin YH; Miao WJ; Sheng WH; Hung CC
    Am J Gastroenterol; 2009 Apr; 104(4):877-84. PubMed ID: 19259078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
    Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
    Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS.
    Lesi OA; Kehinde MO; Oguh DN; Amira CO
    Niger Postgrad Med J; 2007 Jun; 14(2):129-33. PubMed ID: 17599111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent weapon in the battle against HIV: your own immune system.
    Proj Inf Perspect; 2002 Mar; (34):14-6. PubMed ID: 12038300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
    Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC
    Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 vaccine clinical trials: the Brazilian experience.
    Ersching J; Pinto AR
    Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccines against HIV need international partnerships.
    Autran B; Debré P; Walker B; Katlama C
    Nat Rev Immunol; 2003 Jun; 3(6):503-8. PubMed ID: 12776210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.